Literature DB >> 32505873

Incidence of and risk factors for surgical site infection after colorectal surgery: a multiple-center prospective study of 3,663 consecutive patients in China.

Tie-Ying Hou1, Hui-Quan Gan2, Jing-Fang Zhou1, Ya-Jie Gong1, Liu-Yi Li3, Xin-Qiang Zhang2, Yue Meng2, Jie-Rong Chen2, Wei-Jiang Liu2, Long Ye2, Xiao-Xiao Wang1, Yun-Hu Zhao1, Yu Zhang4.   

Abstract

BACKGROUND: Surgical site infection (SSI) after colorectal surgery (CRS) remains a significant problem for its negative clinical outcomes. However, it is poorly understood in China. This study aims to investigate the incidence, risk factors and microbiology of SSI after CRS.
METHODS: A nationwide prospective multicenter design was applied. Patients in 19 Chinese hospitals from 2015 to 2018 were prospectively monitored for SSI after CRS. Demographic data, hospital characteristics, and potential perioperative risk factors were collected and analyzed, using univariate and multivariate logistic regression models.
RESULTS: Among 3,663 study participants, 134(3.66%) episodes of SSI were identified. The incidence rate of SSI decreased from 5.9 infections per 100 procedures in 2015 to 3.1 infections per 100 procedures in 2018 (incidence rate ratio, 0.52; 95% CI, 0.28-0.94). The SSI rates were 1.88, 4.15, 6.27 and 11.58 per 100 operations for the National Nosocomial Infections Surveillance system (NNIS) risk index categories of 0, 1, and 2 or 3, respectively. Escherichia coli (54/134, 40.3%) and Klebsiella pneumoniae (10/134, 7.5%) were the most frequently isolated microorganisms. A high prevalence of antibiotic resistance were observed in our study, with rates of extended spectrum beta-lactamase-producing or carbapenem-resistant Escherichia coli and Klebsiella pneumonia of 50.0%(27/54) and 30.0%(3/10) respectively. Preoperative hospital stay ≥ 48h (OR=2.28, 95% CI: 1.03-5.02, P=0.042) and contaminated or dirty wound (OR=3.38, 95% CI: 1.88-6.06, P=4.50×10-5) were significantly associated with increasing risk of SSI after CRS.
CONCLUSION: A statistically significant but modest decrease in the incidence rate of CRS SSI over the 4-year study period was observed in this study. Noticeably, the relatively high rates of multidrug-resistant pathogens causing SSI after CRS should be alert, while more studies with large population are needed due to the small number of isolates identified in our survey.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  China; Colorectal surgery; Prevalence; Risk factor; Surgical site infection

Year:  2020        PMID: 32505873     DOI: 10.1016/j.ijid.2020.05.124

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  4 in total

1.  Real-World Outcomes of Patients Undergoing Open Colorectal Surgery with Wound Closure Incorporating Triclosan-Coated Barbed Sutures: A Multi-Institution, Retrospective Database Study.

Authors:  Barbara H Johnson; Pragya Rai; Se Ryeong Jang; Stephen S Johnston; Brian Po-Han Chen
Journal:  Med Devices (Auckl)       Date:  2021-02-24

2.  Use of gentamicin-collagen sponge (Collatamp® G) in minimally invasive colorectal cancer surgery: A propensity score-matched study.

Authors:  Kil-Yong Lee; Jaeim Lee; Youn Young Park; Seong Taek Oh
Journal:  PLoS One       Date:  2022-03-28       Impact factor: 3.240

3.  Differences in risk factors for surgical site infection between laparotomy and laparoscopy in gastrointestinal surgery.

Authors:  Momoe Utsumi; Terumasa Yamada; Kazuo Yamabe; Yoshiteru Katsura; Nariaki Fukuchi; Hiroki Fukunaga; Masahiro Tanemura; Junzo Shimizu; Yoshinori Kagawa; Shogo Kobayashi; Hidekazu Takahashi; Koji Tanaka; Tsunekazu Mizushima; Hidetoshi Eguchi; Nana Nakayama; Kiyoko Makimoto; Yuichiro Doki
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

4.  Operating room architecture is not a risk factor for surgical site infections.

Authors:  Thorsten Jentzsch; Lucas Kutschke; Patrick O Zingg; Mazda Farshad
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.